Test Needed to Diagnose Polycythemia Vera
Order JAK2 mutation testing (JAK2V617F) as the first confirmatory test when polycythemia vera is suspected in a patient with elevated hemoglobin/hematocrit.
Diagnostic Algorithm
When you encounter a patient with erythrocytosis, follow this structured approach:
Step 1: Confirm Elevated Red Cell Parameters
First, document the elevation using hemoglobin, hematocrit, or red cell mass:
- Men: Hemoglobin >16.5 g/dL or Hematocrit >49%
- Women: Hemoglobin >16.0 g/dL or Hematocrit >48%
Step 2: Determine Testing Priority Based on Clinical Presentation
If polycythemia is accompanied by leukocytosis or thrombocytosis, order JAK2 mutation testing immediately as your first-line diagnostic test 4. This presentation strongly suggests PV rather than secondary causes.
If polycythemia is isolated (no leukocytosis or thrombocytosis), consider secondary causes first before ordering JAK2 testing 4. However, JAK2 testing remains the definitive test to confirm PV once secondary causes are excluded.
Step 3: JAK2 Mutation Testing - The Cornerstone
JAK2V617F mutation testing captures >95% of PV cases 1, 5, 3. This single test, when positive in the context of elevated hemoglobin/hematocrit, essentially confirms the diagnosis when combined with one minor criterion 1.
The WHO revised criteria specifically elevated JAK2 mutation status to a major criterion because it is:
- Absent in secondary polycythemia
- Absent in spurious polycythemia
- Present in >97% of true PV cases when combined with elevated red cell parameters 1
Step 4: Confirmatory Tests (Minor Criteria)
After positive JAK2 testing, you need at least one of these minor criteria 1:
- Bone marrow biopsy showing panmyelosis with prominent erythroid and megakaryocytic proliferation
- Serum erythropoietin level below the reference range for normal
- Endogenous erythroid colony formation (rarely used in clinical practice)
The most practical approach: Order serum erythropoietin level alongside JAK2 testing. A low erythropoietin level serves as your minor criterion and helps exclude secondary causes 1, 4.
Alternative Diagnostic Path (JAK2-Negative Cases)
If JAK2 testing is negative but clinical suspicion remains high, you need two minor criteria plus the elevated hemoglobin/hematocrit to diagnose PV 1. This captures the rare <3% of PV cases that are JAK2-negative or have mutation burdens too low to detect.
Critical Pitfalls to Avoid
Don't order red cell mass measurement routinely. The WHO revised criteria deliberately moved away from requiring red cell mass measurement as it's cumbersome, not widely available, and adds little diagnostic value when hemoglobin/hematocrit and JAK2 testing are available 1.
Don't skip JAK2 testing to "rule out secondary causes first" if the patient has thrombocytosis or leukocytosis alongside erythrocytosis. This clinical picture strongly suggests PV, and JAK2 testing should be immediate 4.
Don't rely on clinical features alone. While splenomegaly (36%), pruritus (33%), and erythromelalgia (5.3%) support PV, they're neither sensitive nor specific enough for diagnosis 3.
Why This Approach Prioritizes Patient Outcomes
This JAK2-first strategy directly impacts mortality and morbidity by:
- Enabling rapid identification of patients at high thrombotic risk (16% have arterial thrombosis, 7% have venous thrombosis at or before diagnosis) 3
- Allowing immediate initiation of thrombosis prevention (phlebotomy to hematocrit <45% and aspirin) 2, 3
- Distinguishing PV from secondary causes that don't require cytoreductive therapy
- Identifying patients who need monitoring for progression to myelofibrosis (12.7% risk) or acute leukemia (6.8% risk) 3
The evidence strongly supports that meeting both major criteria (elevated hemoglobin/hematocrit + JAK2 mutation) captures >97% of PV cases 1, making this the most efficient and clinically relevant diagnostic pathway.